Literature DB >> 19402792

Increased CA 19-9 level in patients without malignant disease.

Hye-Ryoun Kim1, Chang-Hyun Lee, Young Whan Kim, Sung Koo Han, Young-Soo Shim, Jae-Joon Yim.   

Abstract

BACKGROUND: The measurement of carbohydrate antigen 19-9 (CA 19-9) is recommended for the diagnosis and follow-up of pancreatic cancer. However, increased CA 19-9 has also been reported in patients with various benign diseases of the lung. We aimed to elucidate the pulmonary radiographic abnormalities and laboratory results associated with increased concentrations of CA 19-9.
METHODS: This study was performed using a case-controlled design. Cases included all participants in a cancer screening program who had an increased CA 19-9 concentration (>37 U/mL), but without a diagnosis of malignancy. Age- and sex-matched participants with normal CA 19-9 levels were enrolled as controls. Laboratory results and radiographic features were compared.
RESULTS: In total, 119 participants with increased CA 19-9 concentrations and 476 controls were included. A higher erythrocyte sedimentation rate (ESR) [adjusted odd ratio (aOR), 1.03; 95% confidence interval (CI), 1.01-1.05], higher hemoglobin A(1c) (HbA(1c)) (aOR, 1.28; 95% CI, 1.05-1.56), bronchiectasis (aOR, 2.48; 95% CI, 1.22-5.02), bronchiolitis (aOR, 3.93; 95% CI, 1.88-8.22), emphysema (aOR, 2.67; 95% CI, 1.32-5.40), and interstitial fibrosis (aOR, 10.62; 95% CI, 2.03-55.44) were independent factors for increased CA 19-9.
CONCLUSIONS: CA 19-9 concentrations, as well as increased ESR and HbA(1c), can be increased in patients with various lung abnormalities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19402792     DOI: 10.1515/CCLM.2009.152

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  28 in total

1.  A migration signature and plasma biomarker panel for pancreatic adenocarcinoma.

Authors:  Seetharaman Balasenthil; Nanyue Chen; Steven T Lott; Jinyun Chen; Jennifer Carter; William E Grizzle; Marsha L Frazier; Subrata Sen; Ann McNeill Killary
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-11

2.  Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology.

Authors:  Nerissa Therese Viola-Villegas; Samuel L Rice; Sean Carlin; Xiaohong Wu; Michael J Evans; Kuntal K Sevak; Marija Drobjnak; Govind Ragupathi; Ritsuko Sawada; Wolfgang W Scholz; Philip O Livingston; Jason S Lewis
Journal:  J Nucl Med       Date:  2013-09-12       Impact factor: 10.057

Review 3.  Challenges of Pancreatic Cancer.

Authors:  Julien Dimastromatteo; Jacob L Houghton; Jason S Lewis; Kimberly A Kelly
Journal:  Cancer J       Date:  2015 May-Jun       Impact factor: 3.360

4.  Epidermoid cyst of the spleen.

Authors:  Quoc Duy Vo; Etienne Monnard; Henri Marcel Hoogewoud
Journal:  BMJ Case Rep       Date:  2013-05-09

5.  The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  J Gastrointest Oncol       Date:  2012-06

6.  Estimation of smooth ROC curves for biomarkers with limits of detection.

Authors:  Leonidas E Bantis; Qingxiang Yan; John V Tsimikas; Ziding Feng
Journal:  Stat Med       Date:  2017-08-07       Impact factor: 2.373

7.  Elevated serum CA 19-9 at screening tests: underlying conditions and role of abdominopelvic CT.

Authors:  Ji Yang Kim; Se Hyung Kim; Soo Young Kim
Journal:  Eur Radiol       Date:  2014-08-12       Impact factor: 5.315

8.  Chronic bronchitis with fungal infection presenting with marked elevation of serum carbohydrate antigen 19-9: a case report.

Authors:  Ping Han; Wei Yan; Yi Luo; Wei Tu; Jia-Yi He; Jing-Mei Liu; Jin Gong; Yun-Wu Wang; Meng-Ke Li; De-An Tian; Huan-Jun Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

9.  Modeling prognostic factors in resectable pancreatic adenocarcinomas.

Authors:  Taxiarchis Botsis; Valsamo K Anagnostou; Gunnar Hartvigsen; George Hripcsak; Chunhua Weng
Journal:  Cancer Inform       Date:  2010-01-20

10.  Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein.

Authors:  Gaetano La Greca; Maria Sofia; Rosario Lombardo; Saverio Latteri; Agostino Ricotta; Stefano Puleo; Domenico Russello
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.